Navigation Links
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Date:11/8/2007

Fong will lead sales and marketing of CTI products

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that Jim Fong has been appointed the company's Vice President, Commercial Operations. Fong joins CTI with more than 20 years of sales and marketing experience. Most recently, Fong was National Sales Director at CV Therapeutics (CVT) in Palo Alto, California, where he led the launch of Ranexa(R) for chronic angina. CTI recently agreed to acquire the drug ZEVALIN(R) from Biogen Idec for development, marketing, and sale in the United States. Closing of the acquisition, which remains subject to closing conditions including obtaining certain third party consents, is expected in mid-November.

"Jim did a great job at the launch of Ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent Camptosar(R), Jim has the ideal credentials to positively impact the ZEVALIN relaunch while optimizing the positioning of our future oncology products like pixantrone," noted James A. Bianco, M.D., President and CEO of CTI.

Fong, who will report directly to Dr. Bianco, will be in charge of directing the sales and promotion of CTI products at the national and international levels. This will include product positioning, promotional programs, reimbursement strategies, and development and training of a national sales force.

"I am very pleased to join the CTI team and help re-establish a strong sales and marketing presence for the company," said Fong. "ZEVALIN is a great product and CTI is on an upward growth path with multiple opportunities for product launches in the coming years."

At CVT, Fong managed a sales team of more than 200 people, including business managers, marketing and sales operations, and the sales training department. Prior to CVT, Fong directed several sales teams and also had previous oncology experience at Pharmacia in launching Camptosar. Fong holds a BS from UCLA in Psychology.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of ZEVALIN and our other potential products include risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN in particular including, without limitation, the potential failure to obtain regulatory approval for label expansion of ZEVALIN, other determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling ZEVALIN. In addition, there is a risk that we may not be able to complete the acquisition of ZEVALIN due to closing conditions, including the need to obtain certain third party consents, or that we may not recognize the full expected value of ZEVALIN in future years. In addition, you should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. WorldHeart Appoints David Pellone Chief Financial Officer
8. Novo Nordisk Appoints New Leader of North American Business
9. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
10. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
11. Resonant Medical Appoints New Vice President of Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy this ... of a new benefit for employees that is uncommon in American business: 12 weeks ... supports me and other employees as new parents. It keeps our family life more ...
(Date:7/24/2017)... ... July 24, 2017 , ... ...      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, ... celebrate the structural topping out of the new Destination Medical Building located ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response ... California Department of Health Care Services, will facilitate the development of a hub ...
(Date:7/24/2017)... Cleveland, OH (PRWEB) , ... July 24, 2017 , ... ... OH on the life-altering neurological condition called essential tremor (ET). The seminar will take ... at 5800 Rockside Woods Blvd., Independence, OH. The program will run from 9 a.m. ...
(Date:7/24/2017)... ... , ... Independence Blue Cross (Independence) and ... program, have signed a five-year agreement that will marshal resources from both organizations ... patients receive. The agreement also signifies Jefferson Health officially joining the Independence ...
Breaking Medicine News(10 mins):
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
Breaking Medicine Technology: